Physician profile
John D Carter
NPI 1447269238
$213,393.48
in general payments reported to CMS, 2019-2025
27 companies · $25K in 2025
The $25K reported for 2025 was more than what 93% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $62K · 2020: $15K · 2021: $12K · 2022: $49K · 2023: $33K · 2024: $18K · 2025: $25K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $64K · Food and Beverage: $7,105 · Travel and Lodging: $3,825 · Education: $43.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $64,200.00 |
| Food and Beverage | $7,104.91 |
| Travel and Lodging | $3,824.96 |
| Education | $43.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $88,322.94 | 2019-2025 | Rinvoq |
| Amgen INC. | $72,035.29 | 2019-2025 | Otezla, Otezla, Tavneos |
| Celgene Corporation | $47,533.82 | 2019 | |
| Aurinia Pharma U.S., INC. | $2,578.47 | 2021-2025 | Lupkynis |
| Ani Pharmaceuticals, INC. | $403.02 | 2025 | Purified Cortrophin Gel |
| Ucb, INC. | $361.32 | 2024-2025 | Bimzelx |
| Glaxosmithkline, LLC. | $341.71 | 2024-2025 | Benlysta |
| Mallinckrodt Hospital Products INC. | $293.68 | 2025 | Acthar |
| Pfizer INC. | $279.21 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $275.95 | 2024-2025 | Saphnelo, Enhertu |
| Novartis Pharmaceuticals Corporation | $193.50 | 2024-2025 | |
| Janssen Biotech, INC. | $180.47 | 2024-2025 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $159.76 | 2024-2025 | Orencia |
| Genzyme Corporation | $149.17 | 2023-2025 | |
| Lilly USA, LLC | $60.93 | 2024-2025 | Taltz |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $39.24 | 2025 | Cuvitru |
| Cardinal Health INC | $33.32 | 2025 | |
| Invivyd INC | $32.59 | 2025 | Pemgarda |
| Radius Health, INC. | $27.02 | 2024 | Tymlos |
| Sandoz INC. | $25.06 | 2025 | Hyrimoz |
| Genentech USA, INC. | $23.85 | 2025 | Actemra |
| Sobi, INC | $22.01 | 2024 | |
| Fresenius Kabi USA, LLC | $21.15 | 2025 | Tyenne |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Carter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.